Cellceutix
Manufacturing · Tennessee, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
9432 Emerald Woods Way, Knoxville, Tenne...Phone Number
(978) 921-4125Website
www.cellceutix.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Cellceutix
Cellceutix is a publicly traded biopharmaceutical company focused on developing innovative medical therapies in dermatology, oncology, anti-inflammatory, and antibiotic fields. The company is advancing several first-in-class drug candidates, including Prurisol for psoriasis, Kevetrin for late-stage ovarian cancer, and Brilacidin, an antibiotic with immunomodulatory properties. Their products are designed to help patients achieve clearer skin and target cancer effectively. Cellceutix aims to leverage unique development approaches and FDA designations to bring these therapies to market.Explore more
Cellceutix Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cellceutix your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Cellceutix has recently received funding, and reach out quickly before it becomes old news!
Click to see if Cellceutix had a recent Job posting/layoffs
Cellceutix, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Cellceutix
Product Launch: Get notified when Cellceutix launches new products
Funding: Get notified immidiatlly once Cellceutix has new funding data
Check out if Cellceutix is spiking on competitors!
Earning: See what the market has to say on Cellceutix recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Cellceutix as Masked Content
Find 2 more new buyers
Compare Similar Companies to Cellceutix
Compare insights from companies similar to Cellceutix, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Cellceutix is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Cellceutix is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Cellceutix.
Cellceutix Tech Stack
A closer look at the technologies used by Cellceutix
Cellceutix News & Media
Innovation Pharmaceuticals Obtains Direct Evidence of Molecular Pathways Modulation in Tumors from First Patients in Kevetrin Ph2a Ovarian Cancer Trial
BEVERLY, Mass., Dec. 27, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc., (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to announce highly encouraging preliminary data from the first patients treated in the Company’s Phase 2a clinical trial (see NCT03042702) of Kevetrin for ovarian cancer.Innovation Pharmaceuticals Completes Final Patient Visit in Phase 2b Study of Oral Prurisol for Psoriasis
BEVERLY, Mass., Dec. 21, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc., (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces all patient follow-up visits have been completed in its Phase 2b clinical study of oral Prurisol in moderate-to-severe chronic plaque psoriasis. Prurisol is being developed as a novel, nonbiologic, orally-delivered psoriasis drug candidate.Innovation Pharmaceuticals Brilacidin Oral Mucositis Program Moving Forward Based Upon Positive Anchoring Phase 2 Results and Increased Brilacidin Franchise Value
BEVERLY, Mass., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today is pleased to provide an update on the developmental plan for Brilacidin, its first-in-class defensin-mimetic drug candidate, for the prevention and treatment of Oral Mucositis (OM). On December 11, 2017, the Company released topline data from a Phase 2 trial. The study met its primary endpoint of reducing the incidence of severe OM experiInnovation Pharmaceuticals Reports Positive Topline Results from Phase 2 Placebo-Controlled Trial of Brilacidin for the Prevention of Oral Mucositis in Head and Neck Cancer Patients; Company Targets a Therapeutic Leadership Position in Global OM Market
BEVERLY, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today presented successful topline results from the Company's randomized, double-blind, placebo-controlled, Phase 2 clinical trial of Brilacidin (see NCT02324335) for the prevention and control of Oral Mucositis (OM) in patients receiving chemoradiation for treatment of Head and Neck Cancer. Brilacidin-OM is being developed under an FDA Fast Trac
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cellceutix
Sign Up For FreeTo access detailed company insights
Cellceutix is a publicly traded biopharmaceutical company focused on developing innovative medical therapies in dermatology, oncology, anti-inflammatory, and antibiotic fields. The company is advancing several first-in-class drug candidates, including Prurisol for psoriasis, Kevetrin for late-stage ovarian cancer, and Brilacidin, an antibiotic with... Read More
